These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33837219)

  • 41. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection.
    Jiang XL; Wang GL; Zhao XN; Yan FH; Yao L; Kou ZQ; Ji SX; Zhang XL; Li CB; Duan LJ; Li Y; Zhang YW; Duan Q; Wang TC; Li ET; Wei X; Wang QY; Wang XF; Sun WY; Gao YW; Kang DM; Zhang JY; Ma MJ
    Nat Commun; 2021 Feb; 12(1):897. PubMed ID: 33563974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19.
    Kutsuna S; Asai Y; Matsunaga A; Kinoshita N; Terada M; Miyazato Y; Nakamoto T; Suzuki T; Saito S; Endo M; Kanda K; Kenji M; Takasaki J; Hojo M; Ishizaka Y; Ohmagari N
    J Infect Chemother; 2021 Jun; 27(6):808-813. PubMed ID: 33531292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection.
    Horspool AM; Kieffer T; Russ BP; DeJong MA; Wolf MA; Karakiozis JM; Hickey BJ; Fagone P; Tacker DH; Bevere JR; Martinez I; Barbier M; Perrotta PL; Damron FH
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33472985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG.
    Schwarzkopf S; Krawczyk A; Knop D; Klump H; Heinold A; Heinemann FM; Thümmler L; Temme C; Breyer M; Witzke O; Dittmer U; Lenz V; Horn PA; Lindemann M
    Emerg Infect Dis; 2021 Jan; 27(1):. PubMed ID: 33058753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March-July 2020.
    Kaufman HW; Chen Z; Meyer WA; Wohlgemuth JG
    Popul Health Manag; 2021 Feb; 24(S1):S35-S42. PubMed ID: 33216694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19).
    Anderson EM; Diorio C; Goodwin EC; McNerney KO; Weirick ME; Gouma S; Bolton MJ; Arevalo CP; Chase J; Hicks P; Manzoni TB; Baxter AE; Andrea KP; Burudpakdee C; Lee JH; Vella LA; Henrickson SE; Harris RM; Wherry EJ; Bates P; Bassiri H; Behrens EM; Teachey DT; Hensley SE
    J Pediatric Infect Dis Soc; 2021 May; 10(5):669-673. PubMed ID: 33263756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.
    Wells PM; Doores KJ; Couvreur S; Nunez RM; Seow J; Graham C; Acors S; Kouphou N; Neil SJD; Tedder RS; Matos PM; Poulton K; Lista MJ; Dickenson RE; Sertkaya H; Maguire TJA; Scourfield EJ; Bowyer RCE; Hart D; O'Byrne A; Steel KJA; Hemmings O; Rosadas C; McClure MO; Capedevilla-Pujol J; Wolf J; Ourselin S; Brown MA; Malim MH; Spector T; Steves CJ
    J Infect; 2020 Dec; 81(6):931-936. PubMed ID: 33068628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.
    Adetifa IMO; Uyoga S; Gitonga JN; Mugo D; Otiende M; Nyagwange J; Karanja HK; Tuju J; Wanjiku P; Aman R; Mwangangi M; Amoth P; Kasera K; Ng'ang'a W; Rombo C; Yegon C; Kithi K; Odhiambo E; Rotich T; Orgut I; Kihara S; Bottomley C; Kagucia EW; Gallagher KE; Etyang A; Voller S; Lambe T; Wright D; Barasa E; Tsofa B; Bejon P; Ochola-Oyier LI; Agweyu A; Scott JAG; Warimwe GM
    Nat Commun; 2021 Jun; 12(1):3966. PubMed ID: 34172732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of SARS-CoV-2-Specific Secretory IgA and Neutralizing Antibodies in the Nasal Secretions of Exposed Seronegative Individuals.
    Chwa JS; Kim M; Lee Y; Cheng WA; Shin Y; Jumarang J; Bender JM; Pannaraj PS
    Viruses; 2024 May; 16(6):. PubMed ID: 38932145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunocompromised Seroprevalence and Course of Illness of SARS-CoV-2 in One Pediatric Quaternary Care Center.
    Freeman MC; Rapsinski GJ; Zilla ML; Wheeler SE
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):426-431. PubMed ID: 33049042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
    Yatim N; Boussier J; Tetu P; Smith N; Bruel T; Charbit B; Barnabei L; Corneau A; Da Meda L; Allayous C; Baroudjian B; Jebali M; Herms F; Grzelak L; Staropoli I; Calmettes V; Hadjadj J; Peyrony O; Cassius C; LeGoff J; Kramkimel N; Aractingi S; Fontes M; Blanc C; Rieux-Laucat F; Schwartz O; Terrier B; Duffy D; Lebbé C
    Sci Adv; 2021 Aug; 7(34):. PubMed ID: 34407944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay.
    Brand I; Gilberg L; Bruger J; Garí M; Wieser A; Eser TM; Frese J; Ahmed MIM; Rubio-Acero R; Guggenbuehl Noller JM; Castelletti N; Diekmannshemke J; Thiesbrummel S; Huynh D; Winter S; Kroidl I; Fuchs C; Hoelscher M; Roider J; Kobold S; Pritsch M; Geldmacher C
    Front Immunol; 2021; 12():688436. PubMed ID: 34093595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset.
    Law JC; Girard M; Chao GYC; Ward LA; Isho B; Rathod B; Colwill K; Li Z; Rini JM; Yue FY; Mubareka S; McGeer AJ; Ostrowski MA; Gommerman JL; Gingras AC; Watts TH
    J Immunol; 2022 Jan; 208(2):429-443. PubMed ID: 34903642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself.
    Ferreira-Gomes M; Kruglov A; Durek P; Heinrich F; Tizian C; Heinz GA; Pascual-Reguant A; Du W; Mothes R; Fan C; Frischbutter S; Habenicht K; Budzinski L; Ninnemann J; Jani PK; Guerra GM; Lehmann K; Matz M; Ostendorf L; Heiberger L; Chang HD; Bauherr S; Maurer M; Schönrich G; Raftery M; Kallinich T; Mall MA; Angermair S; Treskatsch S; Dörner T; Corman VM; Diefenbach A; Volk HD; Elezkurtaj S; Winkler TH; Dong J; Hauser AE; Radbruch H; Witkowski M; Melchers F; Radbruch A; Mashreghi MF
    Nat Commun; 2021 Mar; 12(1):1961. PubMed ID: 33785765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts.
    Kundu R; Narean JS; Wang L; Fenn J; Pillay T; Fernandez ND; Conibear E; Koycheva A; Davies M; Tolosa-Wright M; Hakki S; Varro R; McDermott E; Hammett S; Cutajar J; Thwaites RS; Parker E; Rosadas C; McClure M; Tedder R; Taylor GP; Dunning J; Lalvani A
    Nat Commun; 2022 Jan; 13(1):80. PubMed ID: 35013199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.
    Larsen MD; de Graaf EL; Sonneveld ME; Plomp HR; Nouta J; Hoepel W; Chen HJ; Linty F; Visser R; Brinkhaus M; Šuštić T; de Taeye SW; Bentlage AEH; Toivonen S; Koeleman CAM; Sainio S; Kootstra NA; Brouwer PJM; Geyer CE; Derksen NIL; Wolbink G; de Winther M; Sanders RW; van Gils MJ; de Bruin S; Vlaar APJ; ; ; Rispens T; den Dunnen J; Zaaijer HL; Wuhrer M; Ellen van der Schoot C; Vidarsson G
    Science; 2021 Feb; 371(6532):. PubMed ID: 33361116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.
    Li Y; Xu Z; Lei Q; Lai DY; Hou H; Jiang HW; Zheng YX; Wang XN; Wu J; Ma ML; Zhang B; Chen H; Yu C; Xue JB; Zhang HN; Qi H; Guo SJ; Zhang Y; Lin X; Yao Z; Sheng H; Sun Z; Wang F; Fan X; Tao SC
    Cell Rep; 2021 Jul; 36(2):109391. PubMed ID: 34242574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. T-Cell Epitope Mapping of SARS-CoV-2 Reveals Coordinated IFN-γ Production and Clonal Expansion of T Cells Facilitates Recovery from COVID-19.
    Fan X; Song JW; Cao WJ; Zhou MJ; Yang T; Wang J; Meng FP; Shi M; Zhang C; Wang FS
    Viruses; 2024 Jun; 16(7):. PubMed ID: 39066169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses.
    Files JK; Sarkar S; Fram TR; Boppana S; Sterrett S; Qin K; Bansal A; Long DM; Sabbaj S; Kobie JJ; Goepfert PA; Erdmann N
    JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34143754
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays.
    Kahre E; Galow L; Unrath M; Haag L; Blankenburg J; Dalpke AH; Lück C; Berner R; Armann JP
    Sci Rep; 2021 Jul; 11(1):14893. PubMed ID: 34290329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.